|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1999-2-25
|
|
pubmed:abstractText |
Second- and third-generation chemotherapy protocols for the treatment of aggressive non-Hodgkin's lymphomas (NHL) have considerable, and age-related, toxic effects. In addition, they do not seem to prolong overall survival in comparison to standard CHOP chemotherapy. In this phase II study we investigated the feasibility and efficacy of the addition of etoposide to the conventional CHOP regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1213-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9862052-Adolescent,
pubmed-meshheading:9862052-Adult,
pubmed-meshheading:9862052-Aged,
pubmed-meshheading:9862052-Aged, 80 and over,
pubmed-meshheading:9862052-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9862052-Cyclophosphamide,
pubmed-meshheading:9862052-Doxorubicin,
pubmed-meshheading:9862052-Etoposide,
pubmed-meshheading:9862052-Female,
pubmed-meshheading:9862052-Humans,
pubmed-meshheading:9862052-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9862052-Male,
pubmed-meshheading:9862052-Middle Aged,
pubmed-meshheading:9862052-Prednisone,
pubmed-meshheading:9862052-Survival Analysis,
pubmed-meshheading:9862052-Vincristine
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Hematology and Infectious Diseases, Karolinska Hospital, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
